LOGIN  |  REGISTER
Terns Pharmaceuticals

Latest Pharma and Biotech Obesity Treatment News

iBio and AstralBio Provide Update on Myostatin Program for Obesity

October 10
Last Trade: 2.63 0.01 0.38

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Following early discovery,...Read more


Allurion Technologies Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

October 9
Last Trade: 0.69 -0.01 -2.10

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle mass NATICK, Mass. / Oct 09, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program...Read more


Lexaria Bioscience Updates Current GLP-1 Market

October 8
Last Trade: 3.10 0.04 1.31

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. In 2020 the total market size for GLP-1 drugs was less than $4 billion . That same year, Novo Nordisk® paid $1.8 billion to purchase Emisphere's® SNAC...Read more


Bio-Path Initiates Development of Therapeutic Program for Treatment of Obesity

October 8
Last Trade: 1.13 -0.01 -0.88

HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize...Read more


Mangoceuticals Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

October 3
Last Trade: 0.21 -0.0097 -4.50

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and...Read more


Allurion Technologies Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

October 1
Last Trade: 0.69 -0.01 -2.10

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health NATICK, Mass. / Oct 01, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed...Read more


Mangoceuticals Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

October 1
Last Trade: 0.21 -0.0097 -4.50

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category Dallas, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, proudly announces that its highly anticipated oral...Read more


Amneal Pharmaceuticals and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

October 1
Last Trade: 8.57 0.11 1.30

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonists Agreement provides Amneal with a new high-growth vector to drive long-term value creation Metsera gains high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable...Read more


NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

September 30
Last Trade: 2.56 0.09 3.64

Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced...Read more


Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

September 27
Last Trade: 3.10 0.04 1.31

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a...Read more


Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

September 25
Last Trade: 1.86 0.08 4.49

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera’s proprietary N-Tab™ technology. The...Read more


Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

September 23
Last Trade: 18.44 0.74 4.18

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. / Sep 23, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference...Read more


Novo Nordisk: Monlunabant phase 2a trial in obesity successfully completed

September 20
Last Trade: 120.04 2.51 2.14

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant...Read more


Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

September 10
Last Trade: 26.51 0.37 1.42

Topline results expected in 2Q 2025 CAMBRIDGE, Mass. / Sep 10, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it has completed enrollment in the Phase 2 EMBRAZE trial designed to show...Read more


Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

September 10
Last Trade: 6.30 0.28 4.65

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage...Read more


Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

September 9
Last Trade: 7.67 0.27 3.65

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024...Read more


Allurion Technologies Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

September 5
Last Trade: 0.69 -0.01 -2.10

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events NATICK, Mass. / Sep 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass index...Read more


23andMe: Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

August 28
Last Trade: 0.29 -0.008 -2.67

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients...Read more


First Results from Lexaria's Second GLP-1 Human Pilot Study

August 27
Last Trade: 3.10 0.04 1.31

Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that the first results from human pilot study #2, GLP-1-H24-2 (the "Study"), have been received. Lexaria's DehydraTECH®-processed Rybelsus®...Read more


Eli Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

August 27
Last Trade: 932.06 21.37 2.35

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the...Read more


Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

August 22
Last Trade: 3.10 0.04 1.31

DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide Select DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing...Read more


First Patient Dosed in Phase 2 Clinical Study of Palatin Technologies' Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

August 22
Last Trade: 0.88 0.0002 0.02

Complete enrollment currently expected in 3Q 2024 Topline results expected in 1Q calendar year 2025 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J., Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that...Read more


Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

August 22
Last Trade: 4.29 0.55 14.71

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight...Read more


Eli Lilly: Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight

August 20
Last Trade: 932.06 21.37 2.35

176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the 15 mg dose at end of treatment Results are consistent with the combined pharmacology of GIP and GLP-1 receptor agonism INDIANAPOLIS, Aug. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:...Read more


Defence Therapeutics Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

August 19
Last Trade: 0.59 -0.01 -1.67

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum® technology to increase the half-life and efficacity of the GLP-1...Read more


RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib

August 19
Last Trade: 8.01 -0.09 -1.11

The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034[1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic® and Wegovy® and Eli Lilly's Trulicity® and Mounjaro® and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim's Jardiance® Positive results from multiple in vivo studies show the impact of sphingosine kinase-2 (SPHK2)...Read more


Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

August 14
Last Trade: 18.44 0.74 4.18

 Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Series of R&D Webinars PASADENA, Calif. / Aug 14, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of...Read more


NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

August 13
Last Trade: 2.56 0.09 3.64

No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SAD Part 1 Expected in the Third Quarter of 2024, and from the MAD Part 2 in the First Quarter of 2025 CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company...Read more


Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

August 8
Last Trade: 2.46 0.10 4.24

Median weight decreased from 111 kilograms (245 pounds) to 97 kilograms (214 pounds), representing nearly 13% total body weight loss at 12 months in a hard-to-treat patient population living with obesity and Type 2 Diabetes Median HbA1c also decreased substantially from 9.6% to 7.2% at 12 months in these individuals who remained poorly controlled despite multiple glucose-lowering medications and advanced T2D Real-world results...Read more


NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

August 6
Last Trade: 2.56 0.09 3.64

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has signed a joint research agreement, together with Dong-A ST Co. Ltd. and ImmunoForge, to develop...Read more


Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or debilitating conditions REMAIN-1 pivotal study underway to accelerate pathway for weight maintenance indication for Revita®, with anticipated data readouts beginning in Q4 2024 BURLINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Fractyl...Read more


ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

July 25
Last Trade: 2.32 -0.03 -1.28

WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that obesity and its related metabolic complications has been selected as the lead indication for Inflammasome ASC Inhibitor IC 100. “Obesity, a well-established risk factor for an array of...Read more


Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 24
Last Trade: 65.84 3.39 5.43

Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 In Vivo Data From Novel Amylin Agonist Program Reported at...Read more


Roche: Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

July 17
Last Trade: 39.17 0.35 0.90

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1  Pharmacokinetic data supports a once-daily oral dosing regimen for CT-9961  The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed1  SOUTH SAN FRANCISCO, Calif. / Jul 17, 2024 / Business Wire /...Read more


SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

July 16
Last Trade: 0.22 0.0029 1.31

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office (“USPTO”) was submitted as part of its ongoing collaboration with Clearmind...Read more


Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

July 11
Last Trade: 29.16 -0.18 -0.61

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration enabling studies NEW YORK / Jul 11, 2024 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced that based on...Read more


Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

July 10
Last Trade: 0.72 -0.01 -1.44

CHICAGO, IL / ACCESSWIRE / July 10, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the successful completion of the pilot production and scale-up...Read more


NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

June 26
Last Trade: 2.56 0.09 3.64

Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Ascending Dose Part 2 in the First Quarter of 2025 Planned Part 3 Will Assess Total Weight Loss at 24 Weeks, Exploring Maximum Titratable Dose and Dietary Changes; Interim Data Readout Expected Mid-2026 with Top-Line Data in the Second Half of 2026 Recent Financing of up to $70 million Will Fund the Ongoing...Read more


DarioHealth Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1

New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission NEW YORK, June 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market,...Read more


Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

June 24
Last Trade: 2.46 0.10 4.24

Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility; increases potential U.S. treatment population for Revita by over 6x (from ~4 to ~25 million patients) Company presented preclinical data showing...Read more


Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

June 23
Last Trade: 6.30 0.28 4.65

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “We’re pleased...Read more


Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s ...

June 23
Last Trade: 2.46 0.10 4.24

Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...Read more


NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

June 22
Last Trade: 2.56 0.09 3.64

DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide Data Presented at the ADA 84th Scientific Sessions CAMBRIDGE, Mass., June 22, 2024  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced...Read more


Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

June 21
Last Trade: 7.67 0.27 3.65

FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination...Read more


Allurion Technologies Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

June 20
Last Trade: 0.69 -0.01 -2.10

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11%1 NATICK, Mass. / Jun 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at...Read more


Palatin Technologies Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

June 12
Last Trade: 0.88 0.0002 0.02

Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J., June 12, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on...Read more


Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

June 5
Last Trade: 2.14 0.09 4.39

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage...Read more


Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

June 3
Last Trade: 120.04 2.51 2.14

Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy® Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesity PLAINSBORO, N.J., June 3, 2024 /PRNewswire/ -- Novo Nordisk today...Read more


Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

June 3
Last Trade: 38.32 -0.54 -1.39

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study, in both cases at 12 weeks GSBR-1290 demonstrated generally favorable safety and tolerability results with low AE-related study discontinuations Pharmacokinetic data support dose proportional exposure and once-daily...Read more


Allurion Technologies Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

May 30
Last Trade: 0.69 -0.01 -2.10

Company also announces first commercial agreements for the Virtual Care Suite in the United States NATICK, Mass. / May 30, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial...Read more


Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

May 30
Last Trade: 3.14 0.02 0.64

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for...Read more


Eli Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

May 24
Last Trade: 932.06 21.37 2.35

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new...Read more


Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

May 22
Last Trade: 26.51 0.37 1.42

Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab's ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice; lean mass loss with SRK-439, 1mg/kg dose was equivalent to anti-ActRII antibody, 20mg/kg...Read more


Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

May 22
Last Trade: 49.82 1.85 3.86

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends IMCIVREE® (setmelanotide) as an option for treating obesity and the control of...Read more


Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

May 21
Last Trade: 6.30 0.28 4.65

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly...Read more


Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 20
Last Trade: 2.46 0.10 4.24

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for...Read more


Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

May 16
Last Trade: 39.17 0.35 0.90

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001)  At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss  In a subgroup with pre-diabetes at baseline, CT-388 treatment normalized glycemia in all patients, indicating...Read more


Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

May 15
Last Trade: 0.87 0.04 4.96

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center...Read more


ObeEnd - Pioneering Drug-Free Weight Management Wristband

May 13
Last Trade: 357.97 5.33 1.51

VANCOUVER, BC, May 13, 2024 /PRNewswire/ -- WAT Medical, a leader in innovative healthcare solutions, announces the development of ObeEnd, the world's first weight management wristband backed by clinical evidence showcasing its efficacy in reducing dietary intake. Findings from this groundbreaking study were presented at the Canadian Nutrition Society annual conference in May 2024. According to the World Health Organization (WHO),...Read more


BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

May 8
Last Trade: 1.65 -0.02 -1.09

New therapeutic candidate developed using Company’s patented ThermoStem® platform  Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss  DMF submission and commencement of first-in-human studies targeted for before the end of 2024  Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities  MELVILLE,...Read more


Palatin Technologies Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

May 2
Last Trade: 0.88 0.0002 0.02

Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's metabolic program and the multiple roles for novel melanocortin receptor 4 agonists in treating obesity and weight loss maintenance CRANBURY, N.J., May 2, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE...Read more


Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

April 30
Last Trade: 0.87 0.04 4.96

The Phase 2b study planned to be conducted in 15 clinical sites in the United States  Topline clinical data expected in the fourth quarter calendar year 2024  MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory...Read more


NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

April 17
Last Trade: 2.56 0.09 3.64

Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascending Dose Part 2 Expected in the Third Quarter of 2024 CAMBRIDGE, Mass., April 17, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic...Read more


Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

April 11
Last Trade: 5.14 -0.06 -1.15

LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1% and increased bone mineral content (BMC) by 2.8% Well-tolerated, adverse events (AEs) similar to placebo Potential for use in combination with incretin mimetics (GLP-1/GIP agonists and/or post GLP-1/GIP agonist) or as a...Read more


Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

April 8
Last Trade: 8.22 0.00 0.00

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it is launching a new clinical...Read more


Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

March 27
Last Trade: 0.75 0.0087 1.17

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has...Read more


Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 26
Last Trade: 65.84 3.39 5.43

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused...Read more


Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

March 12
Last Trade: 2.46 0.10 4.24

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control. The human GLP-1 transgene sequence used in RJVA-001 was administered to eight-week-old db/db mice with established disease and resulted in up to 50% blood sugar lowering and 11% weight loss vs vehicle at four weeks after a single...Read more


Teladoc Health Expands Obesity & Weight Management Capabilities

March 7
Last Trade: 9.20 -0.29 -3.06

PURCHASE, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as glucagon-like peptide 1 (GLP-1) agonists and support safe, sustainable weight loss and cardiometabolic health improvement for members. New features include helping plan...Read more


Labcorp Launches Weight Loss Management Testing Solutions

March 7
Last Trade: 216.39 1.49 0.69

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient...Read more


Lexaria Bioscience to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

March 5
Last Trade: 3.10 0.04 1.31

Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested Chronic dosing over a 12-week treatment period Will assess weight loss and blood glucose level control Efficacy through possible brain absorption delivery enhancement to be assessed KELOWNA, BC / ACCESSWIRE / March 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms...Read more


NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

February 29
Last Trade: 2.56 0.09 3.64

First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass., Feb. 29, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has received first site Institutional Review Board (IRB) approval for Alexander Prezioso, M.D., Investigator, Clinical Pharmacology of Miami, in Hialeah,...Read more


Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

February 28
Last Trade: 1.13 0.02 1.80

NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active pharmaceutical ingredient in NPM-139, with the added potential benefit of once-yearly dosing NPM-115 and NPM-139 are miniature, subdermal implants in development for chronic weight management designed to guarantee...Read more


ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications...

February 28
Last Trade: 2.32 -0.03 -1.28

Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2 Diabetes, hypertension, cardiovascular disease, dyslipidemia, and even cancer. The article summarizes data demonstrating that inflammasome activation in fat tissue triggers cell death, known as pyroptosis. Pyroptosis results in systemic release...Read more


Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

February 27
Last Trade: 65.84 3.39 5.43

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed  VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or...Read more


Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

February 22
Last Trade: 49.82 1.85 3.86

Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024  Significant unmet need with 5,000 to 8,000 patients with hypothalamic obesity estimated to be living in Japan  BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on...Read more


Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

February 6
Last Trade: 0.87 0.04 4.96

FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical function while augmenting fat loss in sarcopenic obese or overweight elderly patients on GLP-1 drug for weight loss Phase 2b clinical trial is expected to...Read more


NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

February 1
Last Trade: 2.56 0.09 3.64

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Phase 1 Clinical Trial Expected to Occur in the First Half of 2024 CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic...Read more


Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

January 31
Last Trade: 116.12 0.50 0.43

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in the U.S....Read more


ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

January 31
Last Trade: 2.32 -0.03 -1.28

Insulin resistance (IR), a common feature of childhood obesity which affects 15 million children and adolescents, is the main driver of obesity-related metabolic complications such as Type 2 diabetes, hypertension, and premature heart disease. This study demonstrated that NLRP3 inflammasome activation was highest in obese children with the worst metabolic profile (higher serum glucose levels, a late insulin response to glucose...Read more


Newtopia Launches "GLP-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss Drugs

January 29
Last Trade: 0.02 0.00 0.00

NEWU Enables Path to Positive ROI for Payers, Employers, and Value-Based Providers Burdened by Soaring Health Costs and GLP-1 'Sticker Shock' TORONTO, Jan. 29, 2024 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform for creating habits that prevent, slow and reverse chronic disease, today announced GLP-1 Sustain, a companion program to specifically support and...Read more


World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Technologies Balloon for Pre-Surgical Weight Loss

January 23
Last Trade: 0.69 -0.01 -2.10

Allurion Program is the latest innovation in the NHS’s war against obesity NATICK, Mass. / Jan 23, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only...Read more


Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

January 23
Last Trade: 26.51 0.37 1.42

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity CAMBRIDGE, Mass....Read more


Allurion Technologies' Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships

January 17
Last Trade: 0.69 -0.01 -2.10

Company inks deals with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups NATICK, Mass. / Jan 17, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's...Read more


Allurion Technologies Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

January 11
Last Trade: 0.69 -0.01 -2.10

Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months in over half of the patients treated Results improved with addition of oral GLP-1 agonist semaglutide NATICK, Mass. / Jan 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that...Read more


Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

January 9
Last Trade: 4.29 0.55 14.71

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug ("IND")...Read more


Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

January 8
Last Trade: 0.87 0.04 4.96

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the development of enobosarm for obesity. Glucagon-like peptide-1...Read more


New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

January 5
Last Trade: 0.69 -0.01 -2.10

First of its kind research investigated the impact of the changing weight-loss market on the Allurion Program Research included 172 healthcare professionals (HCPs) and 1663 patients across 64 countries Almost 90% of HCPs believed the Allurion Program was an ideal first-line treatment to achieve >10% body weight loss in a fast and sustainable way NATICK, Mass. / Jan 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:...Read more


Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

January 5
Last Trade: 0.94 0.02 2.18

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type...Read more


Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

January 4
Last Trade: 49.82 1.85 3.86

Phase 3 hypothalamic obesity top-line data expected in 1H2025  Positive reimbursement decision achieved for IMCIVREE® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain  IND application for RM-718 accepted by the FDA  BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB